<DOC>
	<DOCNO>NCT01519167</DOCNO>
	<brief_summary>The objective study evaluate safety dexmedetomidine pediatric population require non-intubated , spontaneous breathing , moderate deep sedation ( NI-MDS ) elective diagnostic therapeutic procedure , expect take 30 minute .</brief_summary>
	<brief_title>Open-Label , Safety Study Evaluating Use Dexmedetomidine Pediatric Subjects Undergoing Procedure-Type Sedation</brief_title>
	<detailed_description>This study design evaluate safety continuous infusion dexmedetomidine ( 1 mcg/kg load dose 0.6 mcg/kg/hr initial maintenance dose titrate 0.2-1.0 mcg/kg/hr ) administer subject require non-intubated , spontaneous breathing , moderate deep sedation ( NI-MDS ) elective diagnostic therapeutic procedure expect take 30 minute .</detailed_description>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>1 . Subject ≥28 week gestational age &lt; 17 year age . Preterm subject ≥28 week &lt; 38 week , gestational age ; ( Note : Gestational age calculate time elapse first day last menstrual period day enrollment . If pregnancy achieve use assist reproductive technology , gestational age calculate add 2 week gestational age calculate . ) 2 . Subject American Society Anesthesiologists ( ASA ) Physical Status I , II III . 3 . Subject require nonintubated , spontaneous breathing , moderate deep sedation ( NIMDS ) operating procedure room intensivist , anesthesiologist dental anesthesiologist attendance . 4 . Scheduled elective procedure fall one follow three population : Noninvasive diagnostic/therapeutic procedure ( NIDTP ) : include ultrasound ( US ) , compute tomography ( CT ) scan , magnetic resonance imaging ( MRI ) , cardiac catheterization , transthoracic echocardiogram ( TTE ) ; Minimally invasive diagnostic/therapeutic procedure ( MIDTP ) : include minimally invasive procedure perform US CT guidance ( e.g . US CTguided solid organ biopsy ) , routine myocardial biopsy cardiac transplant recipient ; Surgical procedure : include small surgical procedure ( e.g . excision , biopsy ) dental procedure ( e.g . extraction , pulpectomy , pediatric rehabilitation dental procedure , filing crown ) . 5 . Duration procedure expect take least 30 minute complete . 6 . If female , subject nonlactating either : 1 . Not childbearing potential , defined premenarche , surgically sterile due bilateral tubal ligation , bilateral oophorectomy hysterectomy . 2 . Of childbearing potential pregnant time baseline practice one follow method birth control : oral parenteral contraceptive , doublebarrier method , vasectomized partner , abstinence sexual intercourse . 7 . Subject 's parent ( ) legally acceptable representative ( ) has/have voluntarily sign date informed consent document approve Institutional Review Board . Assent obtain ageappropriate accord state regulation . 1 . Subjects weight time screen less 1000 g. 2 . Subject receive general anesthesia within 7 day prior study drug administration . 3 . Subject participate experimental/investigational drug study within 30 day prior study drug administration . 4 . Subject exposed dexmedetomidine within 48 hour prior study drug administration . 5 . Subject previously enrol study ( DEX1016 ) . 6 . Subject require endotracheal intubation laryngeal mask airway ( LMA ) . 7 . Subject neurological condition opinion Investigator preclude reliable assessment sedation score . Examples include , limited following : cerebral palsy , autism , severe mental retardation , etc . 8 . Subject central nervous system ( CNS ) disease anticipated potential increase intracranial pressure , uncontrolled seizure disorder and/or know psychiatric illness could confound normal response sedative treatment . 9 . Subject require epidural spinal anesthesia . 10 . Subject receive treatment alpha2 agonist antagonist within 14 day prior study drug administration . 11 . Subject know allergy dexmedetomidine , midazolam fentanyl . 12 . Subject require cardiac catheterization purpose conduct electrophysiology ( EP ) evaluation percutaneous intervention ( i.e . angioplasty ) . 13 . Subject opiate , benzodiazepine , dexmedetomidine alpha2 agonist contraindicate . 14 . Subject receive IV opioid within one hour , oral/intramuscular ( PO/IM ) opioid within four hour , prior start study drug administration . 15 . Subject received preinduction medication ( ie , ketamine , chloral hydrate , benzodiazepine ) within 4 hour prior start study drug administration . 16 . Subject acute myocardial infarction recently diagnose confirmatory laboratory finding within 6 week screen . 17 . Subject moderate severe sleep apnea syndrome . 18 . Subject oxygen saturation ( SpO2 ) ≤90 % screen baseline , except patient know cyanotic heart disease undergoing cardiac catheterization . 19 . Subject bradycardia immediately dose , accord respective age group . ≥28 week &lt; 1 month : Heart Rate ( HR ) &lt; 120 beat per minute ( bpm ) 1 month &lt; 3 month : HR &lt; 100 bpm 3 month &lt; 6 month : HR &lt; 90 bpm 6 month &lt; 1 year : HR &lt; 80 bpm 1 year &lt; 2 year : HR &lt; 70 bpm 2 year &lt; 6 year : HR &lt; 60 bpm 6 year &lt; 12 year : HR &lt; 55 bpm 12 year 17 year : HR &lt; 50 bpm ; Note : Subject reassess 5 minute 20 . Subject hypotension immediately dose , accord respective age group . ≥28 week &lt; 1 month : &lt; 60 mmHg ( systolic blood pressure [ SBP ] ) 1 month &lt; 12 month : &lt; 70 mmHg ( SBP ) 1 year &lt; 10 year : &lt; 70 + ( 2 X age year ) mmHg ( SBP ) 10 year 17 year : &lt; 90 mmHg ( SBP ) ; Note : Subject reassess 5 minute 21 . Subject presence seconddegree thirddegree heart block screen baseline . The presence temporary permanent pacemaker waive exclusion criterion . 22 . Subject acute febrile illness , temperature ( core tympanic ) ≥38.0°C . 23 . Subject condition factor , Investigator 's opinion , might increase risk subject .</criteria>
	<gender>All</gender>
	<minimum_age>28 Weeks</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>